Reports
Sale
Global Cancer Supportive Care Drugs Market Size, Share, Analysis, Forecast: By Drug Type: Antiemetic Drugs, Analgesic Drugs, Colony-stimulating Factors, Bisphosphonates, Anti-infective Drugs, Anti-anemia Drugs, Monoclonal Antibodies, Others; By Cancer Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Cancer Supportive Care Drugs Market Outlook
The global cancer supportive care drugs market size attained a value of USD 20.7 billion in 2023, driven by rising demand for supportive care drugs, increased biosimilar uptake, increased expenditure on the healthcare sector, and the rising accessibility to efficient therapeutic techniques, are expected to aid the market growth. The market is anticipated to grow at a CAGR of 2.3% during the forecast period of 2024-2032 to attain a value of USD 25.3 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
It is estimated that the global cancer burden has risen to 18.1 million new cases and 9.6 million deaths in 2018. The most prominent kinds of cancer with the greatest demand for supportive care drugs are lung and breast cancer.
Properties and Applications
The global cancer supportive care drugs market can be broadly categorised on the basis of its drug class into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
- G-CSFs
- Erythropoietin Stimulating Agents (ESA)
- Antiemetics
- Bisphosphonates
- Opioids
- NSAIDs
- Others
The EMR report looks into the regional markets for cancer supportive care drugs like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Market Analysis
It is anticipated that increased biosimilar uptake, a large number of side effects connected with cancer treatment, increased expenditure on the healthcare sector, and the accessibility to the efficient therapeutic techniques, including target-specific and tailored treatments, are driving the global cancer supportive care drugs industry further. China and India are promising locations for the development of the cancer supportive care drugs industry. Factors such as increasing biosimilar uptake, effective healthcare reforms, and low-cost bases are providing a boost to the market in these two nations.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report presents a detailed analysis of the following key players in the global cancer supportive care drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- F. Hoffmann-La Roche AG
- HELSINN Healthcare SA
- Tesaro
- Novartis International AG
- Heron Therapeutics (NASDAQ: HRTX)
- Merck & Co., Inc. (NYSE: MRK)
- Amgen Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Cancer Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Cancer Supportive Care Drugs Market Overview
6.1 Global Cancer Supportive Care Drugs Market Historical Value (2017-2023)
6.2 Global Cancer Supportive Care Drugs Market Forecast Value (2024-2032)
7 Global Cancer Supportive Care Drugs Market Landscape
7.1 Global Cancer Supportive Care Drugs Company Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cancer Supportive Care Drugs Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Cancer Type
7.2.3 Analysis by Distribution Channel
8 Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cancer Supportive Care Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cancer Supportive Care Drugs Market Segmentation
11.1 Global Cancer Supportive Care Drugs Market by Drug Type
11.1.1 Market Overview
11.1.2 Antiemetic Drugs
11.1.3 Analgesic Drugs
11.1.4 Colony-stimulating Factors
11.1.5 Bisphosphonates
11.1.6 Anti-infective Drugs
11.1.7 Anti-anemia Drugs
11.1.8 Monoclonal Antibodies
11.1.9 Others
11.2 Global Cancer Supportive Care Drugs Market by Cancer Type
11.2.1 Market Overview
11.2.2 Breast cancer
11.2.3 Lung cancer
11.2.4 Colorectal cancer
11.2.5 Prostate cancer
11.2.6 Blood cancer
11.2.7 Others
11.3 Global Cancer Supportive Care Drugs Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital pharmacies
11.3.3 Retail pharmacies
11.3.4 Online pharmacies
11.3.5 Specialty pharmacies
11.4 Global Cancer Supportive Care Drugs Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Cancer Supportive Care Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cancer Supportive Care Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cancer Supportive Care Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cancer Supportive Care Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cancer Supportive Care Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 F. Hoffmann-La Roche AG
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 HELSINN Healthcare SA
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Tesaro
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Novartis International AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Heron Therapeutics
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Merck & Co., Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Amgen Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
24 Global Cancer Supportive Care Drugs Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market for cancer supportive care reached a value of USD 20.7 billion.
The market is anticipated to grow at a CAGR of 4.2% during the forecast period of 2024-2032 to reach a value of USD 25.3 billion by 2032.
The major drivers of the industry, such as the rising demand for supportive care drugs, increased biosimilar uptake, increased expenditure on the healthcare sector, and the rising accessibility to efficient therapeutic techniques, are expected to aid the market growth.
The key market trend guiding the industry growth includes the development of the cancer supportive care drugs.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading drug classes of the product in the industry are G-CSFs, erythropoietin stimulating agents (ESA), antiemetics, bisphosphonates, opioids, and NSAIDs, among others.
The major players in the industry are HELSINN Healthcare SA, F. Hoffmann-La Roche AG, Merck & Co., Inc., Amgen Inc., and Novartis International AG, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER